• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Spark Therapeutics, Inc. engages in gene therapy research, development, manufacturing and clinical trials. The company is developing one-time, life-altering gene therapy treatments to transform the lives of patients and re-imagine the treatment of debilitating diseases. Its initial focus is on treating orphan diseases, and it has demonstrated promising clinical outcomes with its first product candidate targeting rare blinding conditions, which has received both breakthrough therapy and orphan product designation and is in a fully enrolled, pivotal Phase 3 clinical trial. The company also has built a pipeline of product candidates targeting additional blinding conditions, hematologic disorders and neurodegenerative diseases, including a second product candidate targeting another rare blinding condition. Spark Therapeutics was founded by Jeffrey D. Marrazzo, Katherine A. High and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA.
| Market Cap | 4.371 Billion | Shares Outstanding | 38.49 Million | Avg 30-day Volume | 545.792 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -4.81 |
| Price to Revenue | 53.4645 | Debt to Equity | 0.1421 | EBITDA | -240.712 Million |
| Price to Book Value | 10.7974 | Operating Margin | -358.24150000000003 | Enterprise Value | 3.355 Billion |
| Current Ratio | 4.666 | EPS Growth | -2.13 | Quick Ratio | 4.241 |
| 1 Yr BETA | 1.0098 | 52-week High/Low | 0.0 / | Profit Margin | -358.4061 |
| Operating Cash Flow Growth | -161.0033 | Altman Z-Score | 4.2799 | Free Cash Flow to Firm | -158.195 Million |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
29,746,673 | 2019-12-17 | 0 | |
|
No longer subject to file | 2019-12-17 | 0 | |
|
No longer subject to file | 2019-12-17 | 0 | |
|
No longer subject to file | 2019-12-17 | 0 | |
|
ZOTH LOTA S. CHIEF SCIENTIFIC OFFICER |
|
No longer subject to file | 2019-12-17 | 0 |
|
No longer subject to file | 2019-12-17 | 0 | |
|
WEBSTER STEPHEN W CHIEF FINANCIAL OFFICER |
|
No longer subject to file | 2019-12-17 | 0 |
|
No longer subject to file | 2019-12-17 | 0 | |
|
No longer subject to file | 2019-12-17 | 0 | |
|
HIGH KATHERINE A SEE REMARKS |
|
No longer subject to file | 2019-12-17 | 0 |
|
MARRAZZO JEFFREY D CHIEF EXECUTIVE OFFICER |
|
No longer subject to file | 2019-12-17 | 0 |
|
LA BARGE JOSEPH CHIEF LEGAL OFFICER |
|
No longer subject to file | 2019-12-17 | 0 |
|
FAGA DANIEL CHIEF BUSINESS OFFICER |
|
No longer subject to file | 2019-12-17 | 0 |
|
MINGOZZI FEDERICO CHIEF SCIENTIFIC OFFICER |
|
No longer subject to file | 2019-12-17 | 0 |
|
DALTON LISA CHIEF HUMAN RESOURCE OFFICER |
|
No longer subject to file | 2019-12-17 | 0 |
|
LA BARGE JOSEPH CHIEF LEGAL OFFICER LA BARGE JOSEPH CHIEF LEGAL OFFICER |
|
21,882 | 2019-03-19 | 0 |
|
No longer subject to file | 2019-02-27 | 0 | |
|
FUREY JOHN CHIEF OPERATING OFFICER |
|
0 | 2018-04-20 | 0 |
|
0 | 2017-05-31 | 0 | |
|
VIVALDI COELHO ROGERIO CHIEF COMMERCIAL OFFICER |
|
18,716 | 2016-07-15 | 0 |
|
SOFINNOVA VENTURE PARTNERS VIII, L.P. |
|
0 | 2015-01-29 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
